破除不正当交易！医药价格招采信用评价标准更严

Group 1 - The National Healthcare Security Administration (NHSA) has revised the credit evaluation system for drug pricing and procurement to combat improper trading behaviors such as commercial bribery and kickbacks [1][2] - The revision adjusts the levels of dishonesty from four categories to three: "Dishonest," "Severely Dishonest," and "Especially Severely Dishonest," tightening the evaluation standards [1] - The threshold for "Especially Severely Dishonest" due to commercial bribery has been lowered from 2 million yuan to 1 million yuan, while the range for "Severely Dishonest" has been set between 500,000 yuan and 1 million yuan [1] Group 2 - The NHSA has introduced measures for pharmaceutical companies to proactively correct dishonest behaviors, including terminating dishonest actions, legally addressing involved employees and agents, publicly apologizing, eliminating inflated pricing, and returning unreasonable profits [2] - The revision aims to guide pharmaceutical companies to improve quality, enhance efficacy, and comply with sales regulations, encouraging market entry through centralized procurement and national negotiations, thereby reducing reliance on high pricing and high commission structures [2]